The introduction of adjuvant treatment with immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 monoclonal antibodies (anti-PD-1), has improved recurrence-free survival (RFS) in high-risk melanoma patients [1,2,3,4], but not all patients benefit from the treatment. Here, PDCD1 is linked to melanoma.